TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Microbiome profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolome profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major pathologic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Volumetric bone mineral density (BMD) of the lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Intestinal microbiota colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline in Pain Values (kg/cm2) on the Pressure pain threshold measurement (PPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Pain Scores on the Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to pain score greater than 3/10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin -1β levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Right ventricular mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reliability of carotid-femoral Pulse Wave Velocity measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Time t [AUC(0-t)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration [Cmaximum (Max)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of Life Habits
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sensitivity and specificity of the non-invasive genetic method
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Dialysate clearance of phosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HIV-1 Viral Load Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CA19-9 value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean blood loss during surgical procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean post-operative hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Arterio-Venous balances of metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Treatment Success/Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trigeminal neurophysiological changes (amplitude)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Trigeminal neurophysiological changes (latencies)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Trigeminal neurophysiological changes (slope)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Lung Clearance Index 2.5 (LCI2.5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Absolute change in left ventricular mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Daily Average Frequency of Daytime Urinary Incontinence Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Orthodontically induced inflammatory root resorption (OIIRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Quantity of opioid pain medication used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in MAS scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Musculoskeletal sonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Fugl-Meyer assessment for upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Body measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Subjects With Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Progression-free Survival Rate at 18 Months
Endpoint domain: Mortality/survival
Primary endpoint: HBV Reactivation rate
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Solid Tumor Participants With First-Cycle Dose-Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of T-ALL/LBL Participants With First-Cycle DLT
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of intimate partner violence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of Hyperhidrosis Disease Severity Scale (HDSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Durable Complete Response (CR) Assessed by Blinded Independent Central Review
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Durable Complete Response (CR) by Investigator's Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radio-dermatitis grade 2, 3, 4
Endpoint domain: Adverse events/effects
Primary endpoint: Transmission of ESBL-producing E. coli and K. pneumoniae
Endpoint domain: Adverse events/effects
Primary endpoint: serum bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral clearance on Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Loss of ovarian volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Quantity of non-convulsive status epilepticus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants reporting complications, adverse events & serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: HPV risk of ≥ CIN2 in NILM 30+ population
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: HPV risk of ≥ CIN2 in Primary screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to functional recovery after surgery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: evolution of neuropathic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Excretion of SB649868
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of SB-649868
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Warfarin dose requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change of the mean Hb level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent change of the severity of anaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Neonatal/infant survival at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Any Major Adverse Cardiovascular Events (MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean High-sensitive C-Reactive Protein (hsCRP) Value at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Grade 2 or higher toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Steady-state pharmacokinetic parameters (half-life, Cmax, Tmax, AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new catheter-related bloodstream infections
Endpoint domain: Adverse events/effects
Primary endpoint: MP-erMRI Classification Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MP-erMRI Classification Specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative change in pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative change in satisfaction with pain management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative functional level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in IgG4-RD responder index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in muscular strength of thigh
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of anti-therapeutic antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Post-traumatic Stress Disorder Symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician Administered PTSD Scale Itemized Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Serum ALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Deliberate Self-Harm Inventory Youth version (DSHI-Y)
Endpoint domain: Adverse events/effects
Primary endpoint: Pregnancy outcomes in Osteogenesis Imperfecta (OI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Device Incidents
Endpoint domain: Adverse events/effects
Primary endpoint: Yield of malignant cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to onset of change in the patient's clinical condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Distribution Volume (DV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Transit Time (MTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disease control rate (DCR) at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Progress (TTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from zero to infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dECG intervals (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes of 95th percentile of home gait velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Orebro Musculoskeletal Screening Questionnaire-12
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Satisfaction with Cryolipolysis treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Raw score of K-MMSE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bodyweight after 3 and 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bodycomposition after 3 and 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bodyfat distribution after 3 and 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specificity and sensitivity of detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Correct Calls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic sensitivity of exhaled breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic specificity of exhaled breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of exhaled breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-months viral suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from Baseline Insomnia Severity
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change from Baseline Glasgow Sleep Impact Index
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change from baseline in dietary behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Emotional Experiences
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total hip BMD change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intratumoural levels of sex hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Intratumoural steroid sulphatase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Ankle function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Lower tear meniscus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The morphology of meibomian glands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With IHC Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kappa Coefficient as a Measure of Agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social Engagement Latency
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Treatment success defined as Physician Global Assessment (PhGA) of 0 or 1
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Presence of Apical Periodontitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periapical index (PAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decayed, missing, filled teeth (DMFT) index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of three required doses of HPV vaccination
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patients requiring endoscopic removal of BRAVO
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Heart Rate (HR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall survival at 5 Years
Endpoint domain: Mortality/survival
Primary endpoint: Clinically significant changes in oral cavity assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of liver damage due to reperfusion injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: significant toxicity associated with CD34-TK75 transduced donor lymphocytes
Endpoint domain: Adverse events/effects
Primary endpoint: Post-dose PC20 Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in inflammatory biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change in adipocytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: nNO levels measured in ppb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: volatile organic compounds (VOCs) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum LDH level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate to Vinblastine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Relief from dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enamel surface color
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enamel surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose of L-DOS47
Endpoint domain: Adverse events/effects
Primary endpoint: compliance with data collection procedures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: feelings of safety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Return to care behavior
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Acceptability and compliance with methadone maintenance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Change in Alanine Aminotransferase (ALT) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum levels of IL1 beta, TNF alpha, IL2, IL6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: QTcF change from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Who Provided Whole Blood Samples
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Foot pressure in g/cm2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anteroposterior pressure distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety and efficacy of DE-104 ophthalmic solution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Follow-up care with primary care provider
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: number of treatments for intracranial hypertensive episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in CWIS-PSDL Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of patients achieving ASAS 20% response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity, frequency and type of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engagement in WE activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Effectiveness of peer support
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Short Physical Performance Battery score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-morphological progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proliferation and disappearance rates of responding antigen-specific T-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to first breakthrough episode of overt hepatic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain Numeric Rating Scale (NRS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Threshold (kPa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signs of ulnar neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in Leaflet Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urinary Incontinence Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Achieving Target Blood Pressure at Week 14 From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Systolic Blood Pressure From Baseline to Week 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Diastolic Blood Pressure From Baseline to Week 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ocular Surface Residence Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief of bothersome symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: percentage change in body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: proportion of each group that achieve a clinically significant (>=5%) reduction in body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Uric Acid <6 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Drug Liking Visual Analog Scale maximum peak effect (Emax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug Liking Visual Analog Scale Area under the effect curve to 2 hours (AUE0-2h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High Visual Analog Scale maximum peak effect (Emax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High Visual Analog Scale Area under the effect curve to 2 hours (AUE0-2h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients who appreciated music listening
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in weekly Average Daily Pain Score (ADPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Kidney Function (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes